Ascend Wellness

Ascend Wellness Holdings earns a Neutral rating, with a 47.4 composite score and low conviction of one out of five. Fundamentals provide the principal support at 59, reflecting comparatively strong operating-margin, cash-generation, and gross-margin subscores. Regulatory contributes 49, aided by an 80 enforcement subscore but constrained by a 25 cadence result and a neutral US jurisdiction posture. Market contributes 40 because institutional pricing feeds provide no available quote, limiting price-based confirmation. Editorial ranks weakest at 30, consistent with no recent newsroom or brief activity in CIN newsroom coverage. The pillar mix supports balance rather than directional conviction: operating performance offsets weak growth, sparse filings, limited market visibility, and absent editorial momentum.

Licensed fundamentals data show year-over-year revenue contracting by 8.6%, a clear drag reflected in the 41.4 revenue-growth subscore. Gross margin stands near 35.7%, supporting a 59.6 subscore, while the roughly 2.1% operating margin produces the strongest operating subscore at 78.5. EBITDA remains positive at approximately $40.5 million, but net income is a loss of roughly $128.4 million. That combination defines a stretched financial condition: positive EBITDA provides operating support without erasing bottom-line pressure or establishing balance-sheet comfort. Market capitalization is approximately $86.9 million, corresponding with a 37.6 size-tier subscore. Primary regulatory filings show no event during the latest 90-day window and one during the latest 180-day window, with the latest filing dated June 25, 2026; that sparse cadence limits regulatory contribution despite no enforcement hits.

The forward catalyst sits squarely within fundamentals, the highest-scoring pillar. Stabilization in revenue would allow the existing gross-margin base and positive operating margin to carry greater weight, while continued EBITDA generation could narrow the disconnect with the substantial net loss. A stronger growth profile would also improve confidence beyond the current low-conviction Neutral stance, particularly while institutional pricing feeds lack a quote and CIN newsroom coverage supplies no independent momentum signal. Regulatory cadence remains secondary because the enforcement profile is already favorable relative to filing frequency. The single most important signal to watch is a return to positive year-over-year revenue growth supported by sustained operating profitability.